Ivermectin, the 2026 Midterm Results and the US Cancer Industry: What Changes, What Doesn't, and What Patients Should Know
Last updated: November 4, 2026. This is a factual explainer, not political commentary. Election results were still being finalized when it was written, and policy outcomes take months to unfold, so check the sources linked below for the latest.
Two stories collided this year: the push to study and sell ivermectin in connection with cancer, and a high-stakes midterm election that may change who controls Congress. Many readers are asking whether the election will change access to ivermectin or the direction of US cancer research. The honest answer is that some things can be said with confidence, and others cannot yet be known.
The short version:
Nothing about ivermectin's FDA status changed on election night. It is approved for certain parasitic infections, not for cancer.
Congress controls federal research funding, which matters for cancer research, but final funding decisions for the current fiscal year are still pending.
State laws on over-the-counter ivermectin are set by state legislatures, not Congress.
The scientific evidence for ivermectin in human cancer has not changed because of the election.

What the Election Results Show So Far
Items | What is reported | Source and timing |
US Senate | Democrats won control; the AP called the Senate majority | TIME live updates, Nov 4 |
US House | Democrats won control; the AP called the House majority | TIME live updates, Nov 4 |
Final counts | Some races may still be uncalled and totals can change | Check AP or your state election office |
These results come from news reports, not an official tally. The new Congress is sworn in in early January 2027, so the current Congress remains in office until then.
Election results: https://time.com/article/2026/11/03/midterm-elections-2026-key-races-live-results-polls-latest-news-updates/
Where Cancer Care and Washington Meet
Area | Where things stand | Who decides |
NIH and NCI research funding | The FY2027 White House budget request called for roughly a 12% cut to NIH, while the NCI's own budget document shows a request of about $7.353 billion, an increase of $8.9 million (0.1%) over FY2026. Congress rejected proposed NIH cuts in FY2026. The House Appropriations Committee approved a FY2027 health spending bill in June with increases for NIH and NCI, and a report said the Senate process had stalled over topline levels | Congress (appropriations) |
NCI ivermectin study | The NCI director said in early 2026 that the agency is running preclinical studies on whether ivermectin can kill cancer cells; some NCI scientists questioned whether the resources were justified, and HHS did not publicly disclose the cost | NCI and HHS leadership; Congress can ask questions through oversight |
Over-the-counter ivermectin | NPR reported in March 2026 that Tennessee, Arkansas, Idaho, Louisiana, and Texas had voted to make ivermectin available over the counter; other states, such as Georgia, have considered similar bills | State legislatures |
FDA status | Ivermectin is approved for certain parasitic infections, not for cancer; approval for cancer would require trial evidence | FDA |
State-funded research | Florida announced state funding for cancer research that includes ivermectin | State government |
NCI FY2027 budget document: https://www.cancer.gov/about-nci/budget/congressional-justification/fy2027-nci-congressional-justification.pdf
What a Change in Congress Can and Cannot Do
What Congress can influence:
Funding for NIH and NCI, through the appropriations process. Funding for cancer research has historically drawn bipartisan support, and Congress rejected proposed NIH cuts last year.
Oversight of how NIH, NCI, FDA, and HHS use their resources, including through hearings and written questions to officials.
Legislation and report language that sets priorities for agencies, such as clinical trial modernization or pediatric cancer research.
What Congress cannot do on its own:
Make ivermectin an FDA-approved cancer treatment. That decision depends on clinical trial evidence reviewed by the FDA.
Change state over-the-counter laws. Those are decided by state legislatures, and some states also held legislative elections this month.
Change the biology. Whether ivermectin works in human cancer will be answered by clinical trials, not by election results.
Anyone predicting dramatic short-term changes should be treated with caution. Appropriations, agency decisions, and clinical research all move slowly.
What the Science Says in 2026
NPR reported in March 2026 that there is currently no good evidence that ivermectin is an effective cancer treatment in humans, and noted that most promising drugs in test tubes and mice do not pan out in people. Laboratory studies show ivermectin can affect cancer cells in several ways, and early trials are examining it alongside immunotherapy, but no completed randomized trial has shown a benefit in patients. For the detailed evidence, see our guides: [Ivermectin in Cancer Care: The 2026 Evidence] and [Ivermectin and Fenbendazole for Cancer: What the 2026 Science Shows]
Easier access does not equal evidence. Oncologists quoted by NPR describe patients who skipped chemotherapy in favor of ivermectin and whose cancer later progressed.
Myths and Facts
Claim | What is accurate |
"The election changed ivermectin's FDA status" | No. The FDA has not approved ivermectin for cancer |
"If a state allows over-the-counter sales, it is proven for cancer" | No. Over-the-counter access is a state law about sale, not evidence of benefit |
"The NCI is studying it, so it works" | No. The NCI work is preclinical, meaning laboratory research, and does not show benefit in patients |
"Funding fights mean cancer research will stop" | Not necessarily. Congress rejected proposed NIH cuts in FY2026, and final FY2027 funding is still being decided |
"A new Congress will immediately change cancer drug policy" | Unlikely. Appropriations, rulemaking, and trials all take months to years |
What Cancer Patients Should Do
Continue your prescribed treatment. Delaying proven therapy while trying an unproven one is the main danger doctors describe.
Tell your oncologist about everything you take, including ivermectin, fenbendazole, and supplements. Some of these drugs affect liver enzymes and can interact with cancer medicines.
Ask about clinical trials. Patients who want to access experimental approaches safely can search ClinicalTrials.gov.
Be careful with online claims, including those from political figures and social media.
If you use ivermectin for an approved purpose, use the dose and duration your prescriber sets. TheMedicineKart stocks ivermectin for patients with a valid prescription for approved uses: [Ivermectin 12mg Tablets]. It is not approved for cancer.
For side-effect management during cancer treatment, see: [Cancer Treatment Side Effects: Complete 2026 Management Guide]
What to Watch Over the Next Few Months
Whether final FY2027 funding for NIH and NCI is settled in the lame-duck session or early in the new Congress.
Any congressional questions or hearings about NCI's ivermectin study, its cost, and its effect on other research.
Further state legislation on over-the-counter ivermectin, including the results of state-level elections.
Results from registered clinical trials of ivermectin combined with immunotherapy.
Any change in FDA or HHS statements on ivermectin.
Frequently Asked Questions
Did the 2026 election change whether ivermectin is approved for cancer?
No. Ivermectin is FDA-approved for certain parasitic infections, not for cancer. Approval for cancer would require clinical trial evidence reviewed by the FDA, which does not change with an election.
Will the new Congress change cancer research funding?
Congress controls federal appropriations, so it matters for NIH and NCI funding. Congress rejected proposed NIH cuts in FY2026, and a House committee approved a FY2027 bill with increases in June, but final FY2027 funding had not been settled in the reports reviewed. It is too early to say what the new Congress will do after it takes office in January 2027.
Is the National Cancer Institute testing ivermectin?
The NCI director said in early 2026 that the agency is running preclinical studies on whether ivermectin can kill cancer cells. Preclinical means laboratory research, which does not show that the drug helps patients. Some NCI scientists questioned whether the resources were justified, and the cost was not publicly disclosed.
Is ivermectin available over the counter in the US?
In some states. NPR reported in March 2026 that Tennessee, Arkansas, Idaho, Louisiana, and Texas had voted to make it available over the counter, and other states have considered similar bills. Federal law has not changed, and over-the-counter sale does not mean the drug is approved or proven for cancer.
Should cancer patients use ivermectin instead of chemotherapy?
No. There is no good evidence that ivermectin treats cancer in humans. Doctors report patients whose cancer progressed after they replaced proven treatment with ivermectin. Talk to your oncologist, continue your prescribed treatment, and ask about clinical trials.





Comments